With an investment of Rs 200 crore, Bharat Serums and Vaccines Global will be able to produce injectables and vaccines at Genome Valley, Hyderabad.
Twitter was used to announce this by Industries and IT Minister KT Rama Rao. His tweet said: Glad to announce that @BSV_Global decided to announce that they will set up a state-of-the-art injectable and vaccine manufacturing facility in @GenomeValley with an investment of Rs 200 crore.
Glad to announce that @BSV_Global decided to announce that they will set up state of the art injectable & vaccine manufacturing facility in @GenomeValley with an investment of ₹200Cr
Thanks to MD of BSV @SanjivSnavangul Ji. This will consolidate Hyd as vaccine Hub of the world pic.twitter.com/XeBO6A8QDP
— KTR (@KTRTRS) April 12, 2022
KT Rama Rao further said: Thanks to the MD of BSV @SanjivSnavangul Ji. This will consolidate Hyderabad as the vaccine hub of the world.
Biotech, pharmaceuticals and biological products are available at the company, he added. Among its segments are gynaecology, assisted reproductive technology, critical care, emergency medicine, nephrology, haematology, and urology.
ALSO READ: US-based Fishin announces an investment of Rs.1000 crore in Telangana
Jagdale Industries sells Tidilan to Bharat Serums and Vaccines
The Advent-backed Bharat Serums and Vaccines (BSV) on Tuesday declared the acquisition of Tidilan (isoxsuprine hydrochloride), a top brand in women’s health from Bengaluru-based Jagdale Industries.
BSV did not provide financial details about the acquisition or annual sales of Tidilan.
There are currently two forms of Tidilan: tablets and injectables. BSV has some of the leading brands in women’s health, such as Rhoclone, Hucog, and AntiD.
Expecting mothers are given Tidilan to relax their uterine muscles and prevent premature labour. In addition to treating and preventing Raynaud’s phenomenon, cerebral vascular insufficiency (arteriosclerosis), and other conditions that cause poor blood flow in the vessels, it belongs to a class of medications called ‘vasodilators’.
BSV is looking to expand its portfolio of women’s health services backed by Advent. A deal last month gave TTK Healthcare access to its women’s health brands by purchasing its pharma business for Rs 805 crore.
Sanjiv Navangul, managing director and CEO of BSV, said, “We are committed to acquiring brands that complement our current women’s health portfolio.”
“We are delighted to add Tidilan to BSV’s Women’s Healthcare portfolio. It will be an important step towards our goal of becoming the top three women’s healthcare players in India,” Navangul added.
(This story has been sourced from a third-party syndicated feed, agencies. Raavi Media accepts no responsibility or liability for the dependability, trustworthiness, reliability, and data of the text. Raavi Media management/ythisnews.com reserves the sole right to alter, delete or remove (without notice) the content at its absolute discretion for any reason whatsoever.)
